"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”
A study looking at a vaccination called TroVax in people with bowel cancer that has spread and cannot be removed with surgery (TaCTiCC)
This study looked at how a vaccine called TroVax affects the immune system in people who have bowel cancer that has spread to another part of the body.
More about this trial
If you have cancer, your immune system tries to attack and kill the cancer cells. Treatments such as TroVax may help the immune system to do this. But other cells in your body can stop your immune system attacking the cancer cells.
Researchers wanted to find out if a chemotherapy drug called cyclophosphamide can help get rid of cells that stop the immune system attacking cancer cells.
The main aim of this study was to see if there is a difference in how well your immune system responds to bowel cancer (the
Summary of results
- 8 didn’t have treatment as part of the study (group 1)
- 9 had cyclophosphamide tablets for 2 weeks (group 2)
- 17 had TroVax injections over 4 months (group 3)
- 18 had cyclophosphamide tablets followed by TroVax injections (group 4)
- 10 out of 17 patients (59%) who hadn’t had TroVax (groups 1 and 2)
- 20 out of 35 patients (57%) who’d had Trovax (groups 3 and 4)
- 15 out of 17 people (88%) who’d had TroVax alone (group 3)
- 13 out of 18 people (72%) who’d had cyclophosphamide and TroVax (group 4)
How to join a clinical trial
Dr Andrew Godkin
Experimental Cancer Medicine Centre (ECMC)
Haematology Clinical Trials Unit University of Cardiff
NIHR Clinical Research Network: Cancer